Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Editorial
. 2019 Dec 4;54(6):1901023.
doi: 10.1183/13993003.01023-2019. Print 2019 Dec.

From ARIA guidelines to the digital transformation of health in rhinitis and asthma multimorbidity

Jean Bousquet  1   2   3   4   5 , Josep M Anto  6   7   8 , Claus Bachert  9 , Sinthia Bosnic-Anticevich  10 , Marina Erhola  11 , Tari Haahtela  12 , Peter W Hellings  13   14 , Piotr Kuna  15 , Oliver Pfaar  16 , Boleslaw Samolinski  17 , Holger J Schünemann  18 , Aziz Sheikh  19 , Dana Wallace  20 ; ARIA study group
Affiliations
Free article
Editorial

From ARIA guidelines to the digital transformation of health in rhinitis and asthma multimorbidity

Jean Bousquet et al. Eur Respir J. .
Free article
No abstract available

PubMed Disclaimer

Conflict of interest statement

Conflict of interest: J. Bousquet reports personal fees from Chiesi, Cipla, Hikma, Menarini, Mundipharma, Mylan, Novartis, Sanofi-Aventis, Takeda, Teva, Uriach (for membership of advisory boards, consultations and honoraria for meeting lectures), and other from KYomed-Innov (shares), outside the submitted work. Conflict of interest: J.M. Anto has nothing to disclose. Conflict of interest: C. Bachert reports consultancy fees from Mylan, Stallergenes, ALK, GSK, Sanofi, Astra-Zeneca and Novartis, outside the submitted work. Conflict of interest: S. Bosnic-Anticevich reports grants from TEVA (unrestricted research grant on inhaler technique), personal fees from TEVA (lecture and advisory board), personal fees from AstraZeneca (lecture and advisory board), personal fees from Boehringer Ingelheim (lecture and advisory board), personal fees from GSK (lecture), personal fees from Sanofi (consultancy), and personal fees from Mylan (consultancy), outside the submitted work. Conflict of interest: M. Erhola has nothing to disclose. Conflict of interest: T. Haahtela reports personal fees from Mundipharma and OrionPharma (lecturing fees), outside the submitted work. Conflict of interest: P.W. Hellings has nothing to disclose. Conflict of interest: P. Kuna has nothing to disclose. Conflict of interest: O. Pfaar reports grants and personal fees from ALK-Abelló, Allergopharma, Stallergenes Greer, HAL Allergy Holding B.V./HAL Allergie GmbH, Bencard Allergie GmbH/Allergy Therapeutics, Lofarma, ASIT Biotech Tools S.A., Laboratorios LETI/LETI Pharma and Anergis S.A., grants from Biomay, Nuvo, Circassia and Glaxo Smith Kline, and personal fees from MEDA Pharma/MYLAN, Mobile Chamber Experts (a GA2LEN Partner), Indoor Biotechnologies and Astellas Pharma Global, outside the submitted work. Conflict of interest: B. Samolinski has nothing to disclose. Conflict of interest: H.J. Schünemann has nothing to disclose. Conflict of interest: A. Sheikh reports that he has served as a member of the BTS/SIGN Asthma Guideline and the EAACI Allergen Immunotherapy Guidelines and is currently a member of the GINA Scientific Board. Conflict of interest: D. Wallace is co-chair of the Joint Task Force on Practice Parameters of the AAAAI/ACAAI.

Publication types